| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ... Annals of Oncology 20 (1), 117-120, 2009 | 576 | 2009 |
| Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease E Kastritis, E Terpos, L Moulopoulos, M Spyropoulou-Vlachou, ... Leukemia 27 (4), 947-953, 2013 | 198 | 2013 |
| The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement … E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, ... Leukemia 22 (12), 2247-2256, 2008 | 142 | 2008 |
| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Cancer Journal 11 (8), 138, 2021 | 127 | 2021 |
| Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post … E Terpos, E Kastritis, D Christoulas, M Gkotzamanidou, ... Annals of Oncology 23 (10), 2681-2686, 2012 | 117 | 2012 |
| Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients … LA Moulopoulos, MA Dimopoulos, E Kastritis, D Christoulas, ... American journal of hematology 87 (9), 861-864, 2012 | 108 | 2012 |
| Cardiac and renal complications of carfilzomib in patients with multiple myeloma MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, D Ziogas, ... Blood advances 1 (7), 449-454, 2017 | 101 | 2017 |
| Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure … MA Dimopoulos, M Roussou, M Gavriatopoulou, E Psimenou, ... American journal of hematology 91 (5), 499-502, 2016 | 101 | 2016 |
| Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma E Kastritis, E Terpos, M Roussou, M Gavriatopoulou, M Migkou, ... Haematologica 102 (3), 593, 2017 | 94 | 2017 |
| Clinical implications of chromosomal abnormalities in multiple myeloma E Terpos, V Eleutherakis-Papaiakovou, MA Dimopoulos Leukemia & lymphoma 47 (5), 803-814, 2006 | 73 | 2006 |
| Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy E Kastritis, M Gavriatopoulou, M Roussou, M Migkou, D Fotiou, DC Ziogas, ... American journal of hematology 92 (7), 632-639, 2017 | 63 | 2017 |
| Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis E Kastritis, I Papassotiriou, G Merlini, P Milani, E Terpos, M Basset, ... Blood, The Journal of the American Society of Hematology 131 (14), 1568-1575, 2018 | 61 | 2018 |
| Efficacy of panobinostat for the treatment of multiple myeloma E Eleutherakis-Papaiakovou, N Kanellias, E Kastritis, M Gavriatopoulou, ... Journal of Oncology 2020 (1), 7131802, 2020 | 59 | 2020 |
| Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide‐based regimens T Bagratuni, E Kastritis, M Politou, M Roussou, E Kostouros, ... American Journal of Hematology 88 (9), 765-770, 2013 | 55 | 2013 |
| Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem‐cell transplantation: results of a single institution, randomized phase … E Eleutherakis‐Papaiakovou, E Kostis, M Migkou, D Christoulas, ... American journal of hematology 85 (11), 863-867, 2010 | 55 | 2010 |
| Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis E Kastritis, IV Kostopoulos, E Terpos, B Paiva, D Fotiou, M Gavriatopoulou, ... Blood cancer journal 8 (5), 46, 2018 | 51 | 2018 |
| Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit MA Dimopoulos, M Roussou, M Gavriatopoulou, D Fotiou, DC Ziogas, ... Blood Cancer Journal 7 (6), e571-e571, 2017 | 51 | 2017 |
| Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin‐1 to angiopoietin‐2 and angiogenin correlate with disease severity A Anagnostopoulos, V Eleftherakis‐Papaiakovou, K Zervas, E Kastritis, ... British journal of haematology 137 (6), 560-568, 2007 | 51 | 2007 |
| Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone E Kastritis, I Dialoupi, M Gavriatopoulou, M Roussou, N Kanellias, ... Blood advances 3 (20), 3002-3009, 2019 | 49 | 2019 |
| Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study M Gavriatopoulou, E Terpos, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Advances 5 (21), 4398-4405, 2021 | 47 | 2021 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of Medicine在 med.uoa.gr 的电子邮件经过验证
